Supplementary figure 1: Intervention bundle adherence and replicability assessment

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **First author** | **Antibiotic Stewardship** | **Contact Precautions** | **Dedicated Equipment** | **Education- Patients** | **Education- Staff** | **Environmental Cleaning** | **Hand Hygiene** | **Isolation and/or Cohorting** | **Proton Pump Inhibitor Stewardship** | **Systems and Workflow** |
|  | Reported adherence measure | TiDier Score | Reported adherence measure | TiDier Score | Reported adherence measure | TiDier Score | Reported adherence measure | TiDier Score | Reported adherence measure | TiDier Score | Reported adherence measure | TiDier Score | Reported adherence measure | TiDier Score | Reported adherence measure | TiDier Score | Reported adherence measure | TiDier Score | Reported adherence measure | TiDier Score |
| Abbett40 |  | 3 |  | 9 |  | 7 |  |  | X | 6 |  | 7 |  | 7 |  | 6 |  |  |  | 8 |
| Apisarnthanarak48 |  |  |  | 3 |  |  |  |  |  | 3 |  | 4 |  | 2 |  |  |  |  |  |  |
| Bishop49 | X | 10 | X | 8 |  |  |  |  |  |  | X | 3 |  | 10 |  |  | X | 3 | X | 8 |
| Brakovich50 | X | 3 | X | 4 |  |  |  |  |  | 4 | X | 5 | X | 7 | X | 3 |  |  | X | 7 |
| Cheng34 |  | 11 |  | 4 |  | 2 |  |  |  | 3 | X | 8 |  | 5 |  | 2 |  |  |  |  |
| Gulihar25 | X | 9 |  |  |  |  | X | 3 |  | 3 |  | 4 |  | 4 |  | 3 |  |  |  |  |
| Hanna41 |  |  |  | 5 |  | 2 |  |  | X | 4 | X | 3 | X | 2 |  | 1 |  |  |  |  |
| Lai47 |  |  |  | 2 |  |  |  |  | X | 3 | X | 7 | X | 2 | X | 2 |  |  |  |  |
| Marufu26 | X | 8 |  |  | X | 3 |  |  | X | 2 | X | 7 | X | 4 |  | 2 |  |  | X | 7 |
| Mattner27 |  |  |  |  |  |  |  |  | X | 1 |  | 1 | X | 1 |  | 1 |  |  |  |  |
| Mermel44 | X | 10 | X | 10 |  | 10 |  |  | X | 3 | X | 12 | X | 6 |  |  |  |  | X | 11 |
| Muto38 | X | 8 | X | 10 |  |  |  |  | X | 6 | X | 9 | X | 7 | X | 9 |  |  | X | 8 |
| Oleastro28 | X | 5 | X | 3 |  |  | X | 2 | X | 2 | X | 6 | X | 3 | X | 3 | X | 2 | X | 7 |
| Power29 | X | 11 |  |  |  |  | X | 11 | X | 11 | X | 10 | X | 11 | X | 8 |  |  |  |  |
| Price30 | X | 5 | X | 7 |  |  |  |  |  |  |  |  |  |  | X | 6 |  |  |  |  |
| Salgado46 |  |  | X | 9 |  |  |  |  |  |  | X | 5 | X | 5 |  |  |  |  |  |  |
| Stone31 | Xa | 8 |  |  |  |  |  |  |  |  |  |  | X | 9 |  |  |  |  | X | 7 |
| Struelens32 | Xb | 4 | X | 4 |  |  |  |  |  |  | X | 9 | X | 3 | X | 3 |  |  | X | 7 |
| Suzuki35 | X | 6 | X | 9 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | X | 9 |
| Valiquette37 | X | 12 |  |  | X | 3 |  |  | X | 9 | X | 8 |  |  | X | 6 |  |  |  |  |
| Weiss39 | Xc | 5 | X | 5 |  |  | X | 4 | X | 8 | X | 11 | X | 8 | X | 5 |  |  | X | 7 |
| Whitaker42 | X | 2 | X | 7 |  |  | X | 5 | X | 4 | X | 9 | X | 7 |  | 8 |  |  | X | 9 |
| White33 | X | 10 |  |  |  |  |  |  | X | 6 |  | 7 | X | 7 | X | 9 |  | 4 | X | 10 |
| Wong-McClure43 | X | 3 | X | 5 |  |  |  |  |  |  |  | 8 | X | 3 | X | 3 |  |  |  |  |
| You36 |  |  | X | 6 |  |  |  |  | X | 6 | X | 6 | X | 6 | X | 6 |  |  |  |  |
| Zafar45 |  |  | X | 11 | X | 10 |  |  | X | 10 | X | 9 | X | 11 | X | 11 |  |  | X | 10 |

Note: In the reported adherence measure column, an “X” means that an adherence measure was reported for that bundle component and a blank means that one was not. A blank in the TiDier score column means that the study did not do this intervention.

aCephalosporin usage decreased from an average of 387 g/100 patients in the nine-months before the intervention to an average of 166 g/100 patients in the nine-month period after the intervention was enacted.

bThe number of clindamycin doses decreased 10% after the intervention, compared to the 12-month period before intervention implementation.

bFluroquinolone consumption decreased 17.8% from 128.10 daily doses per 1,000 patient days in 2002-2003, at the start of the CDI outbreak, to 105.33 daily doses per 1,000 patient days in 2004-2005. This subsequently increased up to 150.89 daily doses per 1,000 patient days in 2006-2007.